Alliancebernstein L.P. Trims Holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)

Alliancebernstein L.P. reduced its holdings in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) by 12.9% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 53,870 shares of the company’s stock after selling 8,000 shares during the period. Alliancebernstein L.P. owned approximately 0.08% of ORIC Pharmaceuticals worth $435,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. JPMorgan Chase & Co. raised its holdings in ORIC Pharmaceuticals by 3.8% during the third quarter. JPMorgan Chase & Co. now owns 35,251 shares of the company’s stock worth $361,000 after purchasing an additional 1,279 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its position in shares of ORIC Pharmaceuticals by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 14,963 shares of the company’s stock valued at $121,000 after purchasing an additional 1,395 shares during the period. PNC Financial Services Group Inc. increased its stake in shares of ORIC Pharmaceuticals by 22.9% during the 4th quarter. PNC Financial Services Group Inc. now owns 13,517 shares of the company’s stock valued at $109,000 after acquiring an additional 2,520 shares during the last quarter. Swiss National Bank boosted its holdings in shares of ORIC Pharmaceuticals by 5.4% in the 4th quarter. Swiss National Bank now owns 62,400 shares of the company’s stock valued at $504,000 after purchasing an additional 3,200 shares during the last quarter. Finally, Rhumbline Advisers lifted its stake in shares of ORIC Pharmaceuticals by 4.6% in the 4th quarter. Rhumbline Advisers now owns 93,319 shares of the company’s stock valued at $753,000 after purchasing an additional 4,072 shares in the last quarter. 95.05% of the stock is currently owned by institutional investors and hedge funds.

ORIC Pharmaceuticals Price Performance

NASDAQ ORIC opened at $4.77 on Monday. The firm has a market capitalization of $338.80 million, a PE ratio of -2.62 and a beta of 1.38. ORIC Pharmaceuticals, Inc. has a 12 month low of $3.90 and a 12 month high of $14.67. The company’s 50 day simple moving average is $6.72 and its 200 day simple moving average is $8.48.

ORIC Pharmaceuticals (NASDAQ:ORIC) last issued its quarterly earnings results on Tuesday, February 18th. The company reported ($0.51) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.01. Sell-side analysts anticipate that ORIC Pharmaceuticals, Inc. will post -2.17 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently issued reports on ORIC shares. Wedbush reiterated an “outperform” rating and set a $20.00 price objective on shares of ORIC Pharmaceuticals in a research note on Thursday, March 20th. JPMorgan Chase & Co. upped their target price on ORIC Pharmaceuticals from $21.00 to $22.00 and gave the company an “overweight” rating in a report on Wednesday, February 26th. Cantor Fitzgerald restated an “overweight” rating on shares of ORIC Pharmaceuticals in a research report on Tuesday, January 14th. Guggenheim reiterated a “buy” rating on shares of ORIC Pharmaceuticals in a research report on Wednesday, February 26th. Finally, HC Wainwright reissued a “buy” rating and issued a $21.00 price objective on shares of ORIC Pharmaceuticals in a report on Friday, February 21st. Nine research analysts have rated the stock with a buy rating, According to MarketBeat, ORIC Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $18.86.

About ORIC Pharmaceuticals

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.